AnchorDx’s UriFind Bladder Cancer Assay in the US; UroMems Initiates Smart Implant to Treat Stress Urinary Incontinence; FDA 510(k) Clearance to NeuroLogica’s BodyTom 64; CE-IVD Mark Approval to SeekInCure’s Recurrence Monitoring Kit Gets; Ypsomed and CamDiab’s Automated Insulin Dosing System; Boston Scientific to Acquire Apollo Endosurgery

MedTech News Updates for AnchorDx, UroMems, NeuroLogica, Ypsomed

AnchorDx Clinical Trial Enrols First Patient for its UriFind® Bladder Cancer Assay in the US On November 23, 2022, AnchorDx, announced the first patient enrollment for its clinical trials of the UriFind® bladder cancer assay in the United States.  The UriFind® bladder cancer assay clinical trial in the United States, involving more than 1,000 patients… Continue reading AnchorDx’s UriFind Bladder Cancer Assay in the US; UroMems Initiates Smart Implant to Treat Stress Urinary Incontinence; FDA 510(k) Clearance to NeuroLogica’s BodyTom 64; CE-IVD Mark Approval to SeekInCure’s Recurrence Monitoring Kit Gets; Ypsomed and CamDiab’s Automated Insulin Dosing System; Boston Scientific to Acquire Apollo Endosurgery

Key Insights and Analysis Into the Point of Care Diagnostics Market

Point of Care Diagnostics Market Forecast, Demand, and Growth

In recent years, the healthcare industry has witnessed immense growth in the screening and diagnostics segment. The incorporation of new-age technologies is bringing several life-saving revolutions to the market and improving the overall health outcomes for the patient. Digitization, innovation, newer hybrid business models, and the use of real-time health data and metrics are providing… Continue reading Key Insights and Analysis Into the Point of Care Diagnostics Market

Antibody-Drug Conjugate: The Smart Biological Bomb

Antibody Drug Conjugates for Cancer Treatment in Asia Healthcare Market

Antibody-drug conjugate (ADCs) is a new emerging class of highly potent pharmaceutical drugs, which is a great combination of chemotherapy and immunotherapy. Over the past couple of decades, antibody-drug conjugates have revolutionized the field of cancer chemotherapy. ADCs are composed of 3 parts: an antibody drug, a cytotoxic payload, and a chemical linker protein to… Continue reading Antibody-Drug Conjugate: The Smart Biological Bomb

C4X Discovery and AstraZeneca Signs Deal; FDA Rejects Spectrum’s Poziotinib; Orphan Drug Designation to Tenaya’s Gene Therapy; EC Approves Regeneron’s Libtayo; Response Letter to Poziotinib for Metastatic NSCLC Harboring HER2 Exon 20 Mutations; Japan Approves Trastuzumab Deruxtecan for HER2+ Breast Cancer

Pharma News for AstraZeneca, Regeneron, Tenaya, Daiichi, C4X Discovery

C4X Discovery Holdings and AstraZeneca Signs Exclusive USD 402 Million Global License C4X Discovery Holdings has signed an exclusive global license with AstraZeneca worth up to USD 402 million for the development and commercialization of the NRF2 Activator program. The agreement will allow AstraZeneca to develop and market an oral therapy for the treatment of… Continue reading C4X Discovery and AstraZeneca Signs Deal; FDA Rejects Spectrum’s Poziotinib; Orphan Drug Designation to Tenaya’s Gene Therapy; EC Approves Regeneron’s Libtayo; Response Letter to Poziotinib for Metastatic NSCLC Harboring HER2 Exon 20 Mutations; Japan Approves Trastuzumab Deruxtecan for HER2+ Breast Cancer

Nascent Advancements and Emerging Therapies in Chronic Pulmonary Hypertension Treatment Market

Chronic Pulmonary Hypertension Treatment Market

Chronic pulmonary hypertension (CPH) encompasses a heterogeneous group of disorders with the common feature of elevated pulmonary vascular resistance, accounting for approximately 42 million cases in 7MM in 2021. As per DelveInsight’s analysis, the 7MM prevalence is expected to increase at a considerable CAGR of 0.35% during the study period 2019–2032. The CPH prevalence is… Continue reading Nascent Advancements and Emerging Therapies in Chronic Pulmonary Hypertension Treatment Market

Evaluating Key Advancements and Emerging Therapies in EGFR-Non Small Cell Lung Cancer Treatment Market

EGFR-NSCLC Treatment Market Dynamics

Non-small cell lung cancer (NSCLC) is the most common cancer, accounting for approximately 85% of the total lung cancers in the United States. Almost 230K new cases were diagnosed in 2022 alone. Moreover, significant deaths were recorded at the end of the same year, accounting for almost 130K deaths. As per DelveInsight’s analysis, it’s estimated… Continue reading Evaluating Key Advancements and Emerging Therapies in EGFR-Non Small Cell Lung Cancer Treatment Market

ESMO Asia 2022: Role of EGFR and ALK mutations in the East Asian Lung Cancer Market

EGFR and ALK mutations in the East Asian Lung Cancer Market

Lung Cancer presents a heavy health and economic burden in Asia, being the most common form of cancer, with 60% of the world’s lung cancers being diagnosed there. Lung cancer is also present in more than 30% of non-smokers in Asia, specifically in adenocarcinomas, which is a subtype largely defined by oncogenic driver gene mutations.… Continue reading ESMO Asia 2022: Role of EGFR and ALK mutations in the East Asian Lung Cancer Market

Mainstay Medical’s ReActiv8-C Study; Swing Therapeutics Announced Results from Studies of Stanza; FDA Approves Empatica’s Health Monitoring Platform; FDA Clearance to Persona OsseoTi Keel Tibia System; ClariPi Joins Siemens Healthineers Digital Marketplace; Sony Launches Cloud-based Solution for Flow Cytometry Data Analysis

MedTech News for Empatica, ClariPi, Sony, Mainstay Medical, Zimmer

Mainstay Medical Published Post-Market Clinical Trial Data from Ongoing ReActiv8®-C Study  On November 22, 2022, Mainstay Medical, a medical devices company, announced that the data from the ReActiv8®-C study, a single-centre, real-world study with a one-year clinical follow-up of selected patients, is published.  ReActiv8 is an implantable medical device designed to treat adults suffering from… Continue reading Mainstay Medical’s ReActiv8-C Study; Swing Therapeutics Announced Results from Studies of Stanza; FDA Approves Empatica’s Health Monitoring Platform; FDA Clearance to Persona OsseoTi Keel Tibia System; ClariPi Joins Siemens Healthineers Digital Marketplace; Sony Launches Cloud-based Solution for Flow Cytometry Data Analysis

How is Technology Addressing the Sleeping Disorders?

Major Technology and Devices in Sleeping Disorders Market

Sleep disorders (or sleep-wake disorders) are one of the major health burdens in today’s time. Sleep is a fundamental process in human life and well-being, and these disorders largely remain untreated or, more often, misdiagnosed as psychiatric problems. Sleep disorders affect and change the way that a person sleeps. Sleep restores the body, improves energy… Continue reading How is Technology Addressing the Sleeping Disorders?

FDA Approves Teplizumab to Delay the Onset of Type 1 Diabetes; FDA Backs Ardelyx’s CKD Therapy Xphozah; Merck to Acquire Imago BioSciences; Accelerated Approval to ImmunoGen’s ELAHERE; Regeneron and CytomX Announces Research Collaboration; FDA Grants Priority Review to Epcoritamab R/R LBCL

Pharma News Updates Merck, Regeneron, Provention, Ardelyx, AbbVie

Merck to Acquire Imago BioSciences, Inc. for USD 1.35 Billion While its rumored acquisition of Seagen has yet to materialize, Merck & Co has continued to bolster its pipeline with smaller transactions, the most recent of which was a USD 1.35 billion agreement to acquire Imago BioSciences and its bomedemstat drug candidate for blood disorders.… Continue reading FDA Approves Teplizumab to Delay the Onset of Type 1 Diabetes; FDA Backs Ardelyx’s CKD Therapy Xphozah; Merck to Acquire Imago BioSciences; Accelerated Approval to ImmunoGen’s ELAHERE; Regeneron and CytomX Announces Research Collaboration; FDA Grants Priority Review to Epcoritamab R/R LBCL